TY - JOUR T1 - Q&A with vaccine developer Adrian Hill: ‘Why shouldn’t we have a big push on malaria?’ JF - The Nation's Health JO - Nations Health SP - 16 LP - 16 VL - 51 IS - 5 AU - Aaron Warnick Y1 - 2021/07/01 UR - http://www.thenationshealth.org/content/51/5/16.2.abstract N2 - Adrian Hill, FMedSci, FRCP, FRS, is director of the Jenner Institute and co-director of the Oxford Martin Program on Vaccines at Oxford University. He co-led research on the Oxford-AstraZeneca COVID-19 vaccine. In April, his team announced that a candidate malaria vaccine had achieved a 77% efficacy in early clinical trials. The vaccine is now in Phase III clinical trials involving a larger population and additional benchmarks on safety and effectiveness. ER -